Skip to content

Castle Biosciences

US · CSTL #3242 by market cap Listed 2019
32.86 -0.55 -1.63%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

✦ Quant Ownership Signal how this is computed

Distributing
  • The number of reporting institutions increased by 6 in the most recent period (2026/Q3).
  • Total institutional ownership fell 5.6 percentage points.

Ownership vs. money flow

Aligned

Institutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
86.41% -5.61pp
Institutions
226 +6
As of
2026/Q3 vs. prior period

Holder types

Mutual Fund59.04%
Hedge Fund20.59%
Public Company3.81%
Individual/Insider1.85%
Government Pension Fund1.08%
Private Company0.91%
Insurance Company0.73%
Sovereign Wealth Fund0.20%
Other11.75%

Top holders as of 2026-09-30

BlackRock 11.21% · 3.45M sh
RTW Investments, LP 9.02% · 2.78M sh
Principal Global Investors, LLC 4.87% · 1.50M sh
Vanguard Capital Management, LLC 4.02% · 1.24M sh
Acadian Asset Management LLC 2.86% · 881.86K sh
Allianz Asset Management AG 2.85% · 879.26K sh
Summit Partners Public Asset Management, LLC 2.68% · 824.87K sh
State Street Global Advisors 2.61% · 804.68K sh
Geode Capital Management, LLC 2.58% · 793.90K sh
Vanguard Portfolio Management, LLC 2.33% · 716.67K sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 5 buys · 45 sells

NameRoleStake
Derek Maetzold Chief Executive Officer 0.51%
Kristen Oelschlager Chief Operating Officer 0.28%
Ellen Goldberg Independent Director 0.13%
Tiffany Olson Independent Director 0.13%
Tobin Juvenal Chief Commercial Officer 0.13%
Kimberlee Caple Independent Director 0.12%
Daniel Bradbury Independent Chairperson 0.12%
Miles Harrison Independent Director 0.12%
Frank Stokes Chief Financial Officer 0.11%
Rodney Cotton Independent Director 0.11%

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-11-10 Tobin Juvenal Chief Commercial Officer Automatic Disposition -6,116 $32.67–35.04
2026-11-10 Tobin Juvenal Chief Commercial Officer Derivative Exercise and Sale -3,195 $29.50–35.07
2026-11-01 Derek Maetzold Chief Executive Officer Automatic Disposition -14,496 $36.01–36.81
2026-10-27 Tobin Juvenal Chief Commercial Officer Automatic Disposition -6,578 $35.58–36.62
2026-10-25 Tobin Juvenal Chief Commercial Officer Automatic Disposition -3,288 $33.08
2026-10-18 Derek Maetzold Chief Executive Officer Automatic Disposition -14,496 $31.91
2026-10-11 Tobin Juvenal Chief Commercial Officer Automatic Disposition -3,288 $33.64
2026-10-04 Derek Maetzold Chief Executive Officer Automatic Disposition -6,331 $35.57
2026-10-04 Derek Maetzold Chief Executive Officer Intent to Sell (Form 144) -28,992 $36.65
2026-10-04 Derek Maetzold Chief Executive Officer Derivative Exercise and Sale -8,165 $2.39–35.57
2026-09-30 Kristen Oelschlager Chief Operating Officer Derivative Exercise and Sale -4,153 $3.38–36.38
2026-09-29 Tobin Juvenal Chief Commercial Officer Automatic Disposition -6,577 $34.20–35.50
2026-09-20 Derek Maetzold Chief Executive Officer Automatic Disposition -5,916 $35.33
2026-09-20 Derek Maetzold Chief Executive Officer Derivative Exercise and Sale -8,580 $2.39–35.33
2026-09-14 Tobin Juvenal Chief Commercial Officer Automatic Disposition -6,600 $32.32–35.14
2026-09-10 Derek Maetzold Chief Executive Officer Automatic Disposition -5,934 $32.00–32.78
2026-09-10 Derek Maetzold Chief Executive Officer Derivative Exercise and Sale -8,584 $2.39–32.00
2026-08-31 Kristen Oelschlager Chief Operating Officer Derivative Exercise and Sale -4,152 $3.38–34.02
2026-08-30 Tobin Juvenal Chief Commercial Officer Automatic Disposition -1,730 $32.81
2026-08-27 Derek Maetzold Chief Executive Officer Automatic Disposition -6,132 $33.14–33.88

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Castle Biosciences discussion 0 comments

Add a comment